[A23-60] Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 21.12.2023
Project no.:
A23-60
Commission:
Commission awarded on 03.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to prior disease-modifying antirheumatic therapy
- Patients who have had an inadequate response or who have been intolerant to prior conventional disease-modifying antirheumatic therapy: added benefit not proven
- Patients who have had an inadequate response or who have been intolerant to prior therapy with biologic disease-modifying antirheumatic drugs: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-110 | Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-64 | Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A23-61 | Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-62 | Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-105 | Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60 | Commission completed |
Federal Joint Committee (G-BA)
2023-12-21 A G-BA decision was published.